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The role of preoperative serum thyroglobulin and thyroid
auto-antibody levels before histopathological diagnosis of
thyroid cancers
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Samet YALÇIN , Burak Veli ÜLGER , Ömer PARLAK , Ali Erkan UÇAR , Seyyit Muhsin SARIKAYA ,
Mehmet ÖZER1, Birol KORUKLUOĞLU1, Bülent YALÇIN2, Ahmet KUŞDEMİR1

Aim: If a frozen section pathological examination is not performed in unilateral thyroid nodule surgery and the
postoperative pathological diagnosis is cancer, a second operation may be required. Therefore, it was studied whether
serum thyroid auto-antibody levels are useful or not in determining preoperative malignancy in patients with thyroid
disorders.
Materials and methods: It was investigated retrospectively whether there was a correlation between preoperative serum
thyroglobulin (Tg), anti-thyroglobulin antibody (anti-Tg), and anti-thyroid peroxidase antibody (anti-TPO) levels and
thyroid cancer in patients who had undergone thyroidectomy.
Results: Two hundred and eighty-seven patients who had undergone thyroid surgery and whose preoperative serum
levels of Tg, anti-Tg, and anti-TPO had been recorded were included in this study. Only 54 (18.8%) of the patients had a
malignant diagnosis in the postoperative histopathological examination. Sixteen of the patients who had a postoperative
malignant thyroid disease diagnosis (29.6%) had high serum Tg, anti-TPO, and/or anti-Tg levels. The rate of high serum
Tg levels was significant in patients with a benign pathology (49.4% vs. 31.5%, P = 0.018).
Conclusion: It appears that preoperative measurement of serum Tg, anti-TPO, and anti-Tg levels is not a useful method
to predict malign thyroid diseases.
Key words: Thyroid cancers, anti-thyroid antibodies, thyroglobulin

Tiroid kanserlerinin histopatolojik tanı öncesinde serum tiroglobülin ve
tiroid oto-antikorları seviyelerinin rolü
Amaç: Unilateral tiroid nodül cerrahisi sırasında frozen section işlemi yapılamadığı durumlarda, kanser olması
durumunda, hastaların yeniden ameliyat olması gerekebilmektedir. Bu nedenle, tiroid nodüllerinde preoperatif
malignitenin tesbitinde, serum tiroid otoantikor seviyelerinin yeri araştırıldı.
Yöntem ve gereç: Retrospektif olarak, tiroidektomi yapılmış olan hastaların preoperatif serum tiroglobulin (Tg), antitiroglobulin antikoru (anti-Tg) ve anti-tiroid peroksidaz antikoru (anti-TPO) düzeyleri ile tiroid kanserleri arasında bir
ilişki olup olmadığını araştırıldı.
Bulgular: İki yıl içinde preoperatif serum Tg, anti-Tg ve anti-TPO seviyeleri bakılmış ve tiroid cerrahisi yapılmış 287
hasta çalışmaya alındı. Hastaların sadece 54 (% 18,8)’ünde postoperatif histopatolojik tiroid malignitesi tanısı aldı.
Postoperatif tiroid kanseri saptanan bu hastaların 16 (% 29,6) ‘inde serum Tg, anti-TPO ve/veya anti-Tg seviyeleri
yüksek bulundu. Yüksek serum Tg düzeyi saptanma oranı benign grupta yüksekti (% 49,4 vs % 31,5 , P = 0,018).
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Sonuç: Malign tiroid hastalıklarını önceden tahmin etmede serum Tg, anti-TPO ve anti-Tg seviyelerinin ölçümü
yardımcı bir yöntem değildir.
Anahtar sözcükler: Tiroid kanserleri, anti-tiroid antikorları, tiroglobulin

Introduction
Thyroid cancer accounts for about 1% of all
cancer types and progresses slowly (1). It is the
second most common endocrinological cancer type,
following ovary cancer (2). The prevalence of thyroid
cancer is closely related with environmental factors
and geographical distribution. Although having a
good prognosis differentiated thyroid cancer has the
potential to rarely induce metastases. Though in the
past hyperthyroidism was considered a protector
against thyroid cancer, this approach has now
changed. In the literature rates up to 21% for the
combination of hyperthyroidism and cancer have
been reported (3,4).
Different markers have been used to investigate
residual tissue presence and tumour recurrence in
patients who have undergone surgery for thyroid
cancer. As an example the measurement of serum
thyroglobulin or calcitonin levels can be presented.
In the literature it was underlined that in patients
who been operated on for thyroid cancer, serum
thyroglobulin and thyroglobulin antibody values
could only be more useful than thyroglobulin values
in the examination of persistent and recurrent
cancers (5). Moreover, the sensitivity and specificity
of fine needle aspiration biopsy in the evaluation of
thyroid nodules are around 70% (6-8).
Since frozen section examination is not used
as an intra-operative pathological evaluation in
many hospitals, unilateral lobectomy is performed,
especially in patients with unilateral nodular goitre
and without any findings of macroscopic pathology
in the opposite thyroid lobe during an operation.
When postoperative pathology results reveal
malignancy the patients undergo a second operation
or complementary thyroidectomy (9,10).
If parameters used in the identification of
postoperative residual tumour and recurrent tumour
can also be used to determine the postoperative
malignancy risk, it will be possible to perform the
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most suitable surgical intervention in only one session
in patients with high risk of thyroid malignancy and
thereby to avoid the risk of complications related with
the second surgical operation. Therefore, we planned
this retrospective study to investigate whether
preoperative serum thyroid auto-antibody levels
(anti-TG, anti-TPO, and TG) had predictive value
for preoperative malignancy in patients with thyroid
diseases in the many hospitals where preoperative
frozen-section examination is not performed.
Materials and methods
Our study had a retrospective clinical study
design. It included 287 consecutive patients who
had undergone thyroidectomy in a single centre
between January 2007 and December 2008 and
whose preoperative serum Tg, anti-Tg, and anti-TPO
levels had been measured. Surgical indications of the
patients were giant nodules in 27 patients (9.4%),
follicular carcinoma in 2 patients (0.69%), Graves’
disease in 9 patients (3.13%), Hürthle-cell adenoma
in 6 patients (2.09%), congenital hypothyroidism
in 5 patients (1.74%), multinodular goitre in 52
patients (18.11%), suspicious nodules in 44 patients
(15.33%), papillary carcinoma in 18 patients (6.27%),
toxic diffuse goitre in 61 patients (21.25%), and toxic
multinodular goitre in 63 patients (21.95%). After
the pathological examination, preoperative serum
Tg, anti-Tg, and anti-TPO levels of 54 patients with
malign and 233 patients with benign nodules were
assessed.
Serum auto-antibody levels were measured
with an Immulite 2000 device and using the
chemiluminesence immunometric assay method.
Reference values for Tg were 0-55 ng/mL, for anti-Tg
0-40 IU/mL, and for anti-TPO 0-35 IU/mL.
For statistical analysis of the results obtained in
this study, SPSS (Statistical Package for the Social
Sciences) for Windows 16.0 was used. Mean,
standard deviation, minimum and maximum values,
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when necessary 95% confidence intervals, and for
categorical variables numerical and percentage
values were used to summarise the parameter values.
In multiple comparisons ANOVA (one way analysis
of variance) and for the comparison of 2 values
Student’s t test (independent sample t test) was used
to determine the distribution of all variable groups.
Cross tabulation statistics were used to compare
categorical variables (chi-square, Fisher).
Results
Patient characteristics
In the study, 215 of the patients were (74.9%)
female and 72 (25.1%) were male and the mean age
was 45.21 ± 13.06 years (range, 17-79 years) (Table 1).
Postoperative histopathologic diagnosis
Postoperative pathologic examination results are
given in Table 1. The results revealed benign diseases
in 230 patients (81.2%) and malignant pathologies in
54 patients (18.8%). According to the postoperative
pathological diagnoses, the elevation frequencies in
diagnosis preoperative serum Tg, anti-Tg, and antiTPO levels are shown in Table 2.

Serum anti-TPO, Tg, and anti-Tg levels and their
relationship with the histopathologic examination
results are given in Table 3. There were no significant
differences between patients with nodules classified
as benign and malignant patients according to
the histological findings in terms of age or gender.
In 115 patients (49.4%) among 233 with benign
histopathological features high levels of serum Tg
were identified, while in 17 patients (31.5%) among
54 with malignant histopathologic features high levels
of serum were observed (P = 0.018). Seventy-three
(31.3%) patients in the benign pathology cohort and
15 (27.8%) patients in the malign pathology cohort
had elevated serum anti-TPO levels (P = 0.610).
Sixty-two patients with a benign pathology (26.6%)
had elevated serum anti-Tg levels compared with 14
patients with a malign pathology (25.9%) who had
elevated serum anti-Tg levels (P = 0.918).
Discussion
Since widespread access to healthcare and
technological advancements have contributed to
the diagnoses of certain diseases, thyroid cancer
is diagnosed more frequently and more extensive

Table 1. Patient characteristics by histopathological diagnosis.
Age

Gender

Pathological diagnosis
Year ± SD (range)

Female n (%)

Male n (%)

MNG

46.62 ± 13.16 (17-72)

111 (74.0)

39 (26.0)

HT

45.88 ± 13.16 (24-70)

28 (84.9)

5 (15.1)

FA

37.36 ± 14.29 (19-61)

12 (85.7)

2 (14.3)

DH

38.90 ± 12.19 (18-59)

13 (65.0)

7 (35.0)

TDG

39.7 ± 11.33 (26-55)

5 (55.6)

4 (44.4)

HHA

44.67 ± 13.44 (33-70)

5 (83.3)

1 (16.7)

GT

54 (54-54)

0 (0.0)

1 (100.0)

PTC

45.90 ± 12.14 (18-79)

37 (74.0)

13 (26.0)

FTC

40.00 ± 2.83 (38-42)

2 (100.0)

0 (0.0)

MTC

57.00 ± 9.90 (50-64)

2 (100.0)

0 (0.0)

P - value

0.6

0.377

SD-standard deviation, MNG-multinodular goitre, HT-Hashimoto’s thyroiditis, FA-follicular
adenoma, DH-diffuse hyperplasia, TDG-toxic diffuse goitre, HHA-Hürthle cells adenoma, GTgranulomatous thyroiditis, PTC-papillary thyroid carcinoma, FTC-follicular thyroid carcinoma,
MTC- medullary carcinoma.
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Table 2. Normal or elevated serum anti-TPO, Tg, and anti-Tg levels according to
histopathological diagnosis.
Anti-TPO, n (%)

Pathological
diagnosis

Tg, n (%)

Anti-Tg, n(%)

Normal

Elevated

Normal

Elevated

Normal

Elevated

131 (87.3)

19 (12.7)

67 (44.7)

83 (55.3)

127 (84.7)

23 (15.3)

HT

6 (18.2)

27 (81.8)

25 (75.8)

8 (24.2)

10 (30.3)

23 (69.7)

FA

9 (64.3)

5 (35.7)

7 (50.0)

7 (50.0)

12 (85.7)

2 (14.3)

DH

8 (40.0)

12 (60.0)

13 (65.0)

7 (35.0)

12 (60.0)

8 (40.0)

TDG

1 (11.1)

8 (89.9)

4 (44.4)

5 (55.6)

5 (55.6)

4 (44.4)

HHA

4 (66.7)

2 (33.3)

2 (33.3)

4 (66.7)

4 (66.7)

2 (33.3)

GT

1 (100.0)

0 (0.0)

0 (0.0)

1 (100.0)

1 (100.0)

0 (0.0)

PTC

36 (72.0)

14 (28.0)

36 (72.0)

14 (28.0)

36 (72.0)

14 (28.0)

FTC

2 (100.0)

0 (0.0)

1 (50.0)

1 (50.0)

2 (100.0)

0 (0.0)

MTC

1 (50.0)

1 (50.0)

0 (0.0)

2 (100.0)

2 (100.0)

0 (0,0)

MNG

P - value

P = 0.000

P = 0.04

P = 0.000

MNG-multinodular goitre, HT-Hashimoto’s thyroiditis, FA-follicular adenoma, DH-diffuse
hyperplasia, TDG-toxic diffuse goitre, HHA-Hürthle cells adenoma, GT-granulomatous
thyroiditis, PTC-papillary thyroid carcinoma, FTC-follicular thyroid carcinoma, MTCmedullary thyroid carcinoma.
Table 3. Comparison of elevated serum anti-TPO, Tg, and anti-Tg levels in benign (n = 233)
and malignant (n = 54) pathology groups.

Age, mean ± SD
Gender (M/F)
Elevated anti-TPO, n (%)
Elevated Tg, n (%)
Elevated anti-Tg, n (%)

Benign pathology

Malignant pathology

P - value

45.01 ± 13.30 (17-72)

46.09 ± 12.02 (18-79)

0.59

174/59

41/13

0.849

73 (31.3)

15 (27.8)

0.610

115 (49.4)

17 (31.5)

0.018

62 (26.6)

14 (25.9)

0.918

SD- standard deviation.

and higher numbers of surgical interventions are
performed (2).
In cases where risk of preoperative malignancy
is not well established, adequate surgical resection
cannot be conducted, especially when an
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intraoperative frozen-section examination is not
possible in patients scheduled for thyroidectomy. In
such cases if the postoperative pathological assessment
reveals thyroid cancer it will be possible to perform a
second operation in this patient. The most significant
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complication observed following thyroidectomy
operations is hypocalcemia secondary to recurrent
laryngeal and parathyroid gland damage (5-10). The
likelihood of developing such complications is higher
after the second operation. Therefore, it is advised to
provide adequate surgical intervention in the first
operation. New techniques that will help to predict
the risk of thyroid malignancy in a more accurate way
are required to avoid such undesirable conditions.
In Turkey in recent years thyroid cancer has been
diagnosed more frequently and more extensive and
higher numbers of surgical operations have been
performed (9). Overall, treatment options to be used
in thyroid diseases are surgery, medical treatment, and
radioactive I-131 therapy. Suspicion of malignancy,
pressure symptoms, hyperthyroidism, retrosternal
goitre, and cosmetic reasons are among indications
for thyroidectomy. Among them suspicion of
malignancy is the most frequent indication in clinical
practice (10-16).
However, since a preoperative frozen section
examination is not performed in the majority of
Turkey’s hospitals, a second surgical operation can
be performed based on the postoperative pathologic
findings. Furthermore, patients are inevitably
re-exposed to the risks associated with general
anaesthesia, postoperative complications, cosmetic
problems secondary to incision scar, hypocalcaemia
risk, incision site infection, and such complications
as recurrent laryngeal and superior laryngeal nerve
damage.
Several methods are used to predict malignancy
risk. Fine needle aspiration biopsy (FNAB) of the
thyroid and ultrasonography (US) are the primary
methods. Serum calcitonin levels are also an
important marker for medullary thyroid cancer (17).
In addition, serum calcitonin and carcinoembryonic
antigen levels are used in the diagnosis of recurrent
disease. A standard biochemical marker used in
patients who have undergone thyroidectomy and
been diagnosed with differentiated thyroid cancer in
the pathological findings is serum thyroglobulin level
(18).
In our study there was no significant difference in
elevated preoperative serum anti-Tg and anti-TPO
levels in patients with postoperative pathological
benign and malignancy findings. The frequency of

elevated serum Tg levels was significantly higher
in patients diagnosed with benign nodules (49.4%
vs. 31.5%, P = 0.018). In the literature there are
some trials investigating the importance of serum
anti-Tg levels in the monitoring of differentiated
thyroid cancers. When a total tumour ablation was
performed in differentiated thyroid cancer with
elevated serum anti-Tg level, serum antibody levels
were found to be markedly decreases in 6 months.
However, it was shown that the interval for serum
anti-Tg levels to restore in normal range could
be prolonged. Therefore, the importance of the
tendency of antibody levels to decrease over time
was underlined in intermittent serial serum anti-Tg
follow-up rather than the level of serum anti-Tg (19).
In the monitoring of recurrent and residual diseases
in differentiated thyroid malignancy, it is more
meaningful to take into account the serum Tg and
anti-Tg levels compared with serum Tg monitoring
alone (5,18).
When serum Tg levels are not elevated, it was
shown that the determination of permanently high
serum anti-Tg levels can be utilised in diagnosing
recurrent and residual differentiated thyroid
carcinomas (20). Similarly, in the monitoring of a
papillary thyroid cancer patient, even though serum
Tg levels were too low to measure, high thyroid
auto-antibody levels and TgmRNA (thyroglobulin
m-RNA) presence in serum were confirmed and
in the subsequent follow-up examinations it was
reported that lymph node metastases had developed
in this patient (21).
It was shown that incidence of elevated serum
thyroid auto-antibody levels is significantly higher
in Hashimoto’s thyroiditis, Graves’ disease, and
subacute thyroiditis relative to other thyroid diseases
(22). There have been some studies examining the
relation between thyroid malignancy and thyroid
autoimmunity. In the study by Fiore et al., although
no difference was observed between patients with
benign thyroid nodular disease and patients with
papillary thyroid cancer, it was established that serum
levels increased with increasing severity of lymphatic
infiltrations in papillary thyroid cancer (23). These
data support the idea that increased invasion level
and increased immune response can co-exist in
papillary thyroid cancer. In pathologically diagnosed
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malignancies in our investigations, excluding the
assessment of invasion parameters of tumours such
as lymphatic infiltration level was considered the
most important limiting aspect of the study.
In another study investigating the association
between thyroid autoimmunity and thyroid
malignancy, serum thyroid autoantibody levels in
570 patients who had undergone thyroidectomy,
the presence of thyroid hypoechogenicity, and
histological lymphatic infiltration on ultrasound
were studied and it was reported that none of these
parameters was related with malignancy. While
thyroid auto-antibody was determined in 32/135
patients (23.7%) with thyroid cancer, autoantibody
was observed in 90/435 patients (20.6%) with benign
lesions and this difference was not significant (24).
In other retrospective studies among patients
with solitary thyroid nodules, the results of 197
patients with positive thyroid autoantibody and 393

patients with negative autoantibody obtained with
ultrasound-guided FNAB were evaluated. FNAB
findings were divided into 3 groups as benign,
intermediate risk, and suspicious. The percentage of
patients with malignant nodules was higher in the
group with positive thyroid autoantibody (18.8% vs.
9.2%, P < 0.001). In this study a significant association
between thyroid cancer and thyroid autoimmunity
was established (25). In our study such an association
was not observed.
In conclusion, no diagnostic value of preoperative
serum Tg and thyroid autoantibody levels among
patients with thyroid cancer was established and
pathological assessment with intraoperative frozensection analysis remains valuable. Prospective studies
with new technological imaging or molecular marker
identification techniques are required to obtain
accurate preoperative diagnoses in thyroid cancers.
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